Graft-Vs-Host Disease

>

Latest News

FDA Approves Axatilimab for Chronic Graft-vs-Host Disease
FDA Approves Axatilimab for Chronic Graft-vs-Host Disease

August 14th 2024

The FDA approved axatilimab for adults and children with chronic graft-vs-host disease whose disease progressed after 2 or more lines of systemic therapy.

BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD
BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

August 11th 2024

Matched and Mismatched Unrelated Donors May Confer Similar Survival Rates for HCT
Matched and Mismatched Unrelated Donors May Confer Similar Survival Rates for HCT

July 30th 2024

Responses to Belumosudil Persist at 3 Years in Chronic GVHD
Responses to Belumosudil Persist at 3 Years in Chronic GVHD

May 7th 2024

Patient-Reported Symptoms via Mobile App May Help Expedite GVHD Identification, Treatment
Patient-Reported Symptoms via Mobile App May Help Expedite GVHD Identification, Treatment

April 26th 2024

Video Interviews
Latest CME Events & Activities

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition

December 6, 2024

Register Now!

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

18th Annual New York GU Cancers Congress™

March 28-29, 2025

Register Now!

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

26th Annual International Lung Cancer Congress®

July 25-26, 2025

Register Now!

More News

© 2024 MJH Life Sciences

All rights reserved.